Indegene Ltd Q2FY26 – When Pharma Meets AI and the Result Is a Clinical Case of Profitability (₹804 Cr Revenue, ₹102 Cr PAT, 20.6% ROE, 29.7x P/E)
1. At a Glance
Ladies and gentlemen, welcome to the glamorous marriage of pharma and software, solemnized by Indegene Ltd — the digital pharmacist that doesn’t sell pills, but sells data that sells pills.
The ₹13,257 crore midcap is a digital-first healthcare tech firm, serving 75% of the top 20 global biopharma companies. In Q2FY26, it clocked ₹804 crore in revenue (up 17.1% YoY) and ₹102 crore in PAT (up 11.3% YoY), flaunting margins tighter than a clinical trial NDA.
With a P/E of 29.7x (half the sector average of 45x), a ROE of 20.6%, and negligible debt (₹122 crore), Indegene is that rarest of Indian IT hybrids — one that actually understands what the FDA does.
At ₹552/share, it trades closer to sanity than hype, while expanding across the US, UK, and EU with AI acquisitions. And yes, it pays a tiny dividend too — 0.36%, perhaps just to prove it exists.
So if TCS is the doctor, and Pfizer is the drug dealer, Indegene is the one running the lab analytics and emailing both the results.
2. Introduction
There was a time when “healthcare + IT” meant faxing prescriptions. Indegene turned that into multi-channel marketing, pharmacovigilance, and AI-assisted regulatory filings.
Founded in 1998 in Bengaluru — long before “healthtech” became a LinkedIn buzzword — the company now works with biopharma giants, emerging biotech, and medtech firms across the U.S., Europe, and Asia. Its role? Help companies develop, register, market, and monitor their drugs using data, analytics, and digital tools.
They’re not the ones running clinical trials, but the ones making sure trials don’t run out of data. From digital content creation for doctors to pharmacovigilance case management, Indegene is the unseen digital wing of Big Pharma.
And in FY26, the company turned the microscope on itself — growing top-line by 12% YoY and profit by 20%. With AI platforms like NEXT, Texture, and Cortex, and partnerships with Microsoft and IISc, Indegene is increasingly becoming healthcare’s version of Accenture: less “code for cash” and more “consulting for compliance.”
3. Business Model – WTF Do They Even Do?
Indegene’s business is simple to describe but impossible to replicate: it’s digital transformation for the world’s most heavily regulated industry.
a) Enterprise Commercial Solutions (59% of FY24 revenue): Think of this as the marketing engine of pharma — digital content, campaign management, patient engagement, and omnichannel sales. Indegene helps Pfizer and Novartis run doctor outreach like an influencer campaign (without reels).
b) Omnichannel Activation (12%): AI-enabled digital reps, social media analytics, and predictive marketing tools that target doctors based on behavioral data. Essentially, “Zomato for prescriptions.”
c) Enterprise Medical Solutions (23%): Regulatory content, labeling, and pharmacovigilance handled by digital CoEs — ensuring the drug doesn’t just cure but complies.
d) Enterprise Clinical Solutions (6%): Digitally-enabled patient recruitment and trial data management. In other words, Excel sheets meet ethics committees.
Their NEXT platform suite — featuring tools like NEXT Content Authoring, NEXT Adverse Event Management, and NEXT Analytics — automates content creation, regulatory filing, and campaign optimization.
And that’s what sets them apart — Indegene isn’t a service provider, it’s a platform-led partner. The margins prove it.
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue (₹ Cr)
804
687
761
17.1%
5.7%
EBITDA (₹ Cr)
141
126
155
11.9%
-9.0%
PAT (₹ Cr)
102
92
116
10.9%
-12.1%
EPS (₹)
4.25
3.83
4.85
10.9%
-12.4%
At an annualized EPS of ₹17.0, the P/E = 29.7x — comfortably below its peers.
The topline continues to grow steadily, but profitability took a mild QoQ dip due to M&A expenses. Still, the 19% OPM is better than most midcap IT peers.
5. Valuation Discussion – Fair Value Range
Let’s look through three lenses — and no, not the AI kind.
